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We report a case of a meso-pancreatectomy performed on a pancreatic glucagonoma in a 58 years-old
woman. MP is a conservative surgical treatment consisting in a resection of the body of the pancreas
with the aim of reducing postoperative hormone insufﬁciency.
This approach is curative in benign or low-malignant neoplasm of the central part of the pancreas.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Glucagonoma is a neuroendocrine neoplasm of the pancreas
accounting for less than 10% of the pancreatic neuroendocrine tu-
mors; it was described for the ﬁrst time by Becker in 1942. Patients
with glucagonomas are classically 40e70 years of age with no
signiﬁcant preference for gender [1,2].
These pancreatic tumors usually originate in the body of the
gland and they can be associated with other tumors in Multiple
Endocrine Neoplasia syndrome 1 (MEN 1), but this association is
rare and comprises nomore than 3% of glucagonomas [3]. Diagnosis
of Pancreatic Glucagonoma (PG) is established by bio-humoral
characterization (glucagon, chromogranin A) and instrumental
investigation (CT, EUS) but its presence is uncommon and symp-
toms are often vague; consequently the tumor may be relatively
large when diagnosed. In 80% of cases PG is associated with dia-
betes and weight loss; the prognosis is unfavorable in 75% of cases.
The optimal treatment for Pancreatic Neuroendocrine Tumors is
surgery [4] and they can be safely resected. Malignant cases should
be treated with aggressive radical surgery to achieve complete
tumor resection [5] but in well-differentiated lesion we can
perform a procedure preserving most of the parenchyma, like
partial pancreatectomy.rrarese).
by Elsevier Ltd. All rights reserved2. Case report
A 58 years old woman was admitted to our Emergency
Department for epigastric pain, nausea and weight loss. The pa-
tient had diabetes mellitus and arterial hypertension. Physical
examination revealed nothing pathological and routine laboratory
analyses (WBC, PCR) were normal. Abdominal US revealed
a15  13 mm lesion of the pancreatic corpus with hypoechoic
patterns and positive Doppler evaluation. Abdominal CT described
a microcystic lesion of 19 mm, with disomogenic matter and
positive enhancement in arterial phase. Bio-humoral evaluation of
Chromogranin A, Glucagon, carcinoembryonic antigen, carbohy-
drate antigen 19-9 and ENS (Enolase Neuronal Speciﬁc) was in
range. During EUS (Endoscopic UltraSound) an intrapancreatic
hypoechoic lesion without lymphadenopathy was observed. Bi-
opsy revealed a hypercellular lesion with papillar pattern, muci-
parous secretion and nuclear anomalies. Explorative laparotomy
revealed a capsulated lesion of the pancreatic corpus without
vascular invasion. There was no evidence of intra-abdominal
metastases. We performed a parenchyma preserving meso-
pancreatectomy (MP). Upon exposure the lesion was all intra-
pancreatic and during intraoperative Ultrasound no vascular in-
vasion was conﬁrmed. The pancreas was released by posterior
vessels and the parenchyma was divided at 1 cm proximally and
distally from the lesion. The anatomical preparation was submit-
ted to a pathologist that conﬁrmed the lesion and declared that
the margins were cleared. Reconstruction was accomplished with
anastomosis between the ileus and the tail of the pancreas, per-
formed with absorbable monoﬁlament suture; we performed a
Roux-en-Y with pancreaticojejunostomy reconstruction to distal.
A. Ferrarese et al. / International Journal of Surgery 12 (2014) S123eS125S124pancreatic stump. A pancreatic stent was inserted in Wirsung's
stump tract and the head tract was clamped. We placed a two tube
drain in para-anastomotic position. A glucagon-producer endo-
crine tumor with uncertain biological behavior was diagnosed at
the time of pathologic evaluation. On immunohistochemical
evaluation Chromogranin A, Cytokeratin and Glucagon levels
were positive and Ki67 mutation percentage was 1%. After surgery
an antibiotic therapy was set. On the 7th postoperative day a
pancreatic ﬁstula (Drainage Amy ¼ 15.000) was detected from the
head section, that was solved with a conservative approach,
parenteral nutrition, antibiotic and analgesic therapy. The naso-
gastric tube was removed on the 3rd postoperative day and drains
on the 27th and 30th day. The patient was discharged on the 36th
postoperative day.
A CT scan was performed on the 90th postoperative day and
after 6 and 12 months with no evidence of complications.
The patient has been followed-up as an out-patient for 5 years
and she has no sign of local recurrence or distant metastases.
3. Discussion
Pancreatic endocrine tumors represent a heterogeneous group
with varying tumor biology and prognosis. These neoplasms are
classiﬁed as functional if they are associated with a hormone-
related clinical syndrome caused by hormone release from the
tumor, or non-functional if the tumor is not associated with a
hormone-related clinical syndrome [6]. Glucagonoma is a slow-
growing alpha-cell tumor of the pancreatic islets of Langerhans. It
is characterized by necrolytic migratory erythema (NME), hypo-
aminoacidemia, cheilosis and diabetes mellitus that is found in 80%
of patients with glucagonoma syndrome [7e9].
A glucagonoma may appear as a benign and localized alpha-cell
adenoma but at least 50% of cases will have metastatic disease
when diagnosed [4]. Disease progression is often slow even in the
presence of metastases, and the patients may need sequential
excision of lymph node or liver metastases during a long disease
course, with often 5 years or more between recurrent lesions. In
literature the reported 10-year survival is about 50% [10]. The
optimal treatment for glucagonoma is surgery, but 50% of the tu-
mors have metastasized at time of diagnosis [4,11].
We performed a meso-pancreatectomy because, according to
literature, we believe that the parenchymal preservation is essen-
tial and appropriately selected patients will beneﬁt from extended
central pancreatectomy because of the maintenance of endocrine
and exocrine function [12]. Furthermore, in selected cases of central
pancreatic lesion, central pancreatectomy is associated with less
perioperative morbidity and mortality than extended classic
resection [13,14]. In Adham's series, central pancreatectomy led to
effective preservation of both cephalic and distal pancreatic rem-
nants without a signiﬁcant increase in postoperative morbidity
compared with conventional pancreatectomy [15,16]. Furthermore,
long-term local recurrence after extended central pancreatectomy
is similar to the recurrence rates after extended classic resection
[13,17].
In our case we assisted at the onset of a ﬁstola; in literature
pancreatic ﬁstula and delayed gastric emptying are the most
prevalent complications of pancreatectomy but in the majority of
cases they can be managed by conservative measures [3].
4. Conclusion
In selected cases, the MP is a great technique when performed
by experienced hands. Parenchymal preservation, in order to avoid
endocrine and exocrine pancreatic insufﬁciency, remains a critical
decision for the patients outcome.Ethical approval
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